(0.31%) 5 115.59 points
(0.31%) 38 358 points
(0.34%) 15 982 points
(-0.87%) $83.12
(5.82%) $2.04
(0.39%) $2 356.40
(0.48%) $27.67
(4.04%) $959.35
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $2.97
発行日: 14 2月 2024 @ 23:30
リターン: -41.40%
前回のシグナル: 2月 14 - 02:28
前回のシグナル:
リターン: 2.92 %
Live Chart Being Loaded With Signals
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology...
Stats | |
---|---|
本日の出来高 | 498 902 |
平均出来高 | 1.89M |
時価総額 | 257.96M |
EPS | $0 ( 2024-03-06 ) |
次の収益日 | ( $-0.120 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.87 |
ATR14 | $0.00400 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Sherman Jeffrey W | Buy | 6 502 | Common Stock |
2024-03-15 | Kong Garheng | Buy | 6 474 | Common Stock |
2024-03-15 | Johnson John | Buy | 89 571 | Common Stock |
2024-03-18 | Johnson John | Buy | 215 600 | Common Stock |
2024-03-18 | Johnson John | Sell | 215 600 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.71 |
Last 99 transactions |
Buy: 12 203 668 | Sell: 238 056 |
ボリューム 相関
Xeris Pharmaceuticals Inc 相関 - 通貨/商品
Xeris Pharmaceuticals Inc 財務諸表
Annual | 2024 |
収益: | $163.91M |
総利益: | $124.43M (75.91 %) |
EPS: | $-0.450 |
FY | 2024 |
収益: | $163.91M |
総利益: | $124.43M (75.91 %) |
EPS: | $-0.450 |
FY | 2023 |
収益: | $110.25M |
総利益: | $87.61M (79.47 %) |
EPS: | $-0.700 |
FY | 2022 |
収益: | $110.25M |
総利益: | $87.61M (79.47 %) |
EPS: | $-1.200 |
Financial Reports:
No articles found.
Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。